Accès libre

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients

À propos de cet article

Citez

Figure 1

Overall survival of patients according to regional lymph node status (p = 0.000).
Overall survival of patients according to regional lymph node status (p = 0.000).

Figure 2

Overall survival of patients according to tumour grade of differention G1 and G2 versus G3.
Overall survival of patients according to tumour grade of differention G1 and G2 versus G3.

Figure 3

Overall survival of wtKRAS and mutated KRAS gene patients (p = 0.47).
Overall survival of wtKRAS and mutated KRAS gene patients (p = 0.47).

Figure 4

Overall survival of mutated KRAS patients in codon 12 and 13 (p = 0.40).
Overall survival of mutated KRAS patients in codon 12 and 13 (p = 0.40).

Figure 5

Overall survival of wtBRAF and mutated BRAF gene patients (p = 0.05).
Overall survival of wtBRAF and mutated BRAF gene patients (p = 0.05).

Figure 6

Median overall survival of wtNRAS, codon 61 and 146 patients and mutated NRAS, codon 61 and 146 patients (p = 0.072).
Median overall survival of wtNRAS, codon 61 and 146 patients and mutated NRAS, codon 61 and 146 patients (p = 0.072).

Figure 7

Median time to progression of wtNRAS, codon 61 and 146 patients, and mutated NRAS, codon 61 and 146 patients (p = 0.025).
Median time to progression of wtNRAS, codon 61 and 146 patients, and mutated NRAS, codon 61 and 146 patients (p = 0.025).

Response rate according to systemic treatment

Response rate Systemic chemotherapy+ cetuksimab, number (%) Systemic chemotherapy+ bevacizumab, number (%)
Complete response 7 (13) 6 (17)
Partial response 18 (34) 8 (23)
Stable disease 21 (40) 19 (54)
Progression of disease 7 (13) 2 (6)

Response rate according to mutations in codon 12 and 13

Response rate Codon 12 mutations, number (%) Codon 13 mutations, number (%)
Complete response 6 (12) 2 (12)
Partial response 5 (11) 6 (35)
Stable disease 23 (49) 7 (41)
Progression of disease 13 (28) 2 (12)

Patient’s baseline characteristics

Patient’s characteristics Number (%)
Medium age (years) 62
Gender
female 59 (38)
male 95 (62)
WHO performance status
0 36 (23)
1 109 (71)
2 9 (6)
Tumour location
colon 112 (73)
rectum 42 (27)
Primary metastatic 89 (58)
Liver metastases 68 (44)

Disease characteristics

Disease characteristics Number (%)
pT4 of primary tumour 35 (23)
Affected regional lymph nodes (N)
N0 (no affected regional lymph nodes)
N1 (1 to 3 affected regional lymph nodes) 34 (22)
N2 (more than 3 affected regional lymph nodes) 61 (40) 59 (38)
Vascular invasion 22 (14)
Perineal invasion 25 (16)
Lymphangiosis 27 (17)
Grade of differentiation
G1 (well) 10 (6)
G2 (medium) 131 (85)
G3 (poorly) 13 (8)
KRAS gen
non-mutated (wild-type) 89 (58)
mutated 65 (42)
KRAS mutation
codon 12 48 (73)
codon 13 17 (27)
BRAF gen
non-mutated (wild-type) 150 (97)
mutated 4 (3)

Adverse effects of systemic treatment

Grade 1 n (%) Grade 2 n (%) Grade 3 n (%) Grade 4 n (%)
Haematological
leukopenia 42 (27) 8 (5) 1 (1)
neutropenia 42 (27) 8 (5) 1+1
thrombocytopenia 33 (21) 11 (7) (1+1)*
anaemia 88 (57) 10 (6)
Non-haematological
alopecia 62 (40) 21 (14) / /
fatigue 93 (60) 11 (7) 0 /
nausea 40 (26) 10 (6) 0 /
vomiting 14 (9) 9 (6) 0 0
diarrhea 23 (15) 29 (19) 2 (2) 1 (1)
stomatitis 4 (3) 2 (2) 0 0
hand-foot syndrome 17 (11) 6 (4) 0 /
peripheral sensory neuropathy 32 (21) 8 (5) 0 0
hepatic toxicity 17 (11) 3 (2) 0 0
renal toxicity 0 0 1 (1) 0
acneiform rash 14 (9) 38 (25) 0 0
hypermagnesemia 6 (4) 0 3 (2) 0
allergic reaction to cetuximab 3 (2) 1 (1) 0 0
allergic reactions to oxaliplatin 1 (1) 0 0 0
arterial hypertension 3 (2) 9 (6) 0 /
proteinuria 20 (13) 18 (12) 0 0
bleeding 6 (4) 0 1 (1)
thromboembolic events 0 7 (5) 0 0
wound complications 0 0 0 /
perforation 0 0 0 0
arthralgia 17 (11) 2 (2) 0 0
bladder infection / 3 (2) 0 0
eISSN:
1581-3207
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology